Reported Tuberculosis in the United States, 2017

• Table 1. Tuberculosis Cases, Case Rates per 100,000 Population, Deaths, and Death Rates per 100,000 Population, and Percent Change: United States, 1953–2017
• Table 2. Tuberculosis Cases, Percentages, and Case Rates per 100,000 Population by Hispanic Ethnicity and Non-Hispanic Race: United States, 1993–2017
• Table 3. Tuberculosis Cases and Percentages by Hispanic Ethnicity and Non-Hispanic Race, and by Origin of Birth: United States, 1993–2017
• Table 4. Tuberculosis Cases, Percentages, and Case Rates per 100,000 Population by Age Group: United States, 1993–2017
• Table 5. Tuberculosis Cases, Percentages, and Case Rates per 100,000 Population by Origin of Birth: United States, 1993–2017
• Table 6. Tuberculosis Cases and Percentages among Non-U.S.–Born Persons by the Top 30 Countries of Birth: United States, 2013–2017
• Table 7. Tuberculosis Cases and Percentages by Case Verification Criterion and Site of Disease: United States, 1993–2017
• Table 8. Tuberculosis Cases and Percentages, by Resistance to Isoniazid (INH), Origin of Birth, and Previous History of TB: United States, 1993–2017
• Table 9. Tuberculosis Cases and Percentages, by Multidrug Resistance (MDR), Origin of Birth, and Previous History of TB: United States, 1993–2017
• Table 10. Percentages of Tuberculosis Cases, by Initial Drug Regimen, Use of Directly Observed Therapy (DOT), and Completion of Therapy (COT): United States, 1993–2017
• Table 11. Tuberculosis Cases and Percentages among Persons with HIV Test Results and with HIV Coinfection, by Age Group: United States, 1993–2017
• Table 12. Tuberculosis Cases and Percentages, by Reason Tuberculosis Therapy Was Stopped: United States, 1993–2015
• Table 13. Deaths among Reported Tuberculosis Cases: United States, 2010–2015
• Table 14. Sputum Culture Conversion: United States, 2010–2015
• Table 15. Extrapulmonary Tuberculosis Cases and Percentages by Site of Disease: United States, 2010–2017
• Table 16. National Tuberculosis Genotyping Surveillance Coverage: United States, 2004–2017
• Table 17. National Tuberculosis Genotyping Surveillance Coverage: United States-Affiliated Areas, 2004–2017
• Table 18. Genotyped Tuberculosis Cases with Mycobacterium bovis by Origin of Birth: United States, 2004–2017

• Table 19. Tuberculosis Cases and Percentages among Non-U.S.–Born Persons, by the Top 30 Countries of Birth and Years in the United States before TB Diagnosis: United States, 2017
• Table 20.  Tuberculosis Cases and Rates per 100,000 Population, by Hispanic Ethnicity and Non-Hispanic Race, Sex, and Age Group: United States, 2017
• Table 21.  Tuberculosis Cases among U.S.-Born Persons, by Hispanic Ethnicity and Non-Hispanic Race, Sex, and Age Group: United States, 2017
• Table 22. Tuberculosis Cases among Non-U.S.–Born Persons, by Hispanic Ethnicity and Non-Hispanic Race, Sex, and Age Group: United States, 2017
• Table 23. Tuberculosis Risk Factors, by Origin and Race/Ethnicity: United States, 2017
• Table 24. Characteristics of Tuberculosis Cases in GENType Clusters, by Alert Levels Based on Log-Likelihood Ratios (LLR): United States, 2015–2017
• Table 25. Tuberculosis Cases and Clusters, by Cluster Size: United States, 2015–2017
• Table 26.  Twenty-Five Most Frequently Reported GENTypes among Genotyped Tuberculosis Cases: United States, 2015–2017
• Table 27. Five Most Frequently Reported GENTypes Among Genotyped Tuberculosis Cases: United States-Affiliated Areas, 2015–2017

• Table 28. Tuberculosis Cases and Case Rates per 100,000 Population: Reporting Areas, 2017 and 2016
• Table 29. Tuberculosis Cases and Case Rates per 100,000 Population, Ranked and Grouped by Number of Cases: United States and the District of Columbia, 2017 and 2016
• Table 30. Tuberculosis Cases and Percentages, by Age Group: Reporting Areas, 2017
• Table 31. Tuberculosis Cases and Percentages by Hispanic Ethnicity and Non-Hispanic Race: Reporting Areas, 2017
• Table 32. Tuberculosis Cases and Percentages, U.S.-Born and Non-U.S.–Born Persons: Reporting Areas, 2017
• Table 33. Tuberculosis Cases and Percentages among Non-U.S.–Born Persons, by Number of Years in the United States: Reporting Areas, 2017
• Table 34. Tuberculosis Cases and Percentages, by Pulmonary and Extrapulmonary Disease: Reporting Areas, 2017
• Table 35. Tuberculosis Risk Factors: Reporting Areas, 2017
• Table 36. Primary Reason for Tuberculosis Evaluation: Reporting Areas, 2017
• Table 37. Tuberculosis Cases and Percentages, by Residence in and Type of Correctional Facilities, Ages ≥15 Years: Reporting Areas, 2017
• Table 38. Tuberculosis Cases and Percentages, by Homeless Status, Ages ≥15 Years: Reporting Areas, 2017
• Table 39. Tuberculosis Cases and Percentages, by Residence in Long–Term Care Facilities, Ages ≥15 Years: Reporting Areas, 2017
• Table 40. Tuberculosis Cases and Percentages, by Injecting Drug Use, Ages ≥15 Years: Reporting Areas, 2017
• Table 41. Tuberculosis Cases and Percentages, by Noninjecting Drug Use, Ages ≥15 Years: Reporting Areas, 2017
• Table 42. Tuberculosis Cases and Percentages, by Excess Alcohol Use, Ages ≥15 Years: Reporting Areas, 2017
• Table 43. Tuberculosis Cases and Percentages by Primary Occupation, Ages ≥15 Years: Reporting Areas, 2017
• Table 44. Tuberculosis Cases and Percentages, by Initial Drug Regimen: Reporting Areas, 2017
• Table 45. Culture-Positive Tuberculosis Cases and Percentages with Drug Susceptibility Results, by Resistance to Isoniazid or Multidrug Resistance: Reporting Areas, 2017
• Table 46. Tuberculosis Cases and Percentages, by HIV Status: Reporting Areas, 2017
• Table 47. Tuberculosis Genotyping Surveillance Coverage: Reporting Areas, 2017

• Table 48. Tuberculosis Cases and Percentages, by Directly Observed Therapy (DOT): Reporting Areas, 2015
• Table 49. Tuberculosis Cases and Percentages, by Reason Therapy Was Stopped: Reporting Areas, 2015
• Table 50. Reason Therapy Was Extended Beyond 12 Months: Reporting Areas, 2015
• Table 51.Tuberculosis Cases and Percentages, by Completion of Tuberculosis Therapy (COT): Reporting Areas, 2015
• Table 52. Tuberculosis Cases and Percentages among Persons Completing Therapy for Whom Therapy Was Indicated for ≤1 Year: Reporting Areas, 2011–2015

• Table 53. Tuberculosis Cases and Case Rates per 100,000 Population: Metropolitan Statistical Areas with ≥500,000 Population, 2017 and 2016
• Table 54. Tuberculosis Cases, by Age Group: Metropolitan Statistical Areas with ≥500,000 Population, 2017
• Table 55. Tuberculosis Cases, by Hispanic Ethnicity and Non-Hispanic Race: Metropolitan Statistical Areas with ≥500,000 Population, 2017
• Table 56.Tuberculosis Cases and Percentages, U.S.-Born Persons and Non-U.S.–Born Persons: Metropolitan Statistical Areas with ≥500,000 Population, 2017

Estimates Of Recent Transmission

Figures

• Figure 1. Estimated Cases Attributed to Recent Transmission of Tuberculosis, United States, 2016–2017
• Figure 2. Estimated Percentage of Extensive Recent Transmission of Tuberculosis in Counties with ≥10 Genotyped Cases, United States, 2016–2017

Tables

• Table 57. Counts and Percentages of Tuberculosis Cases Estimated to be Attributed to Overall and Extensive Recent Transmission: Reporting Areas, 2016–2017
• Table 58. Counts and Percentages of Tuberculosis Cases Estimated to be Attributed to Overall and Extensive Recent Transmission: Counties with >5 Percent Estimated Extensive Recent Transmission, 2016-2017
• Table 59. Characteristics of Tuberculosis Cases Estimated to be Attributed to Overall and Extensive Recent Transmission: United States, 2016–2017

• Appendix A: Tuberculosis Case Definition for Public Health Surveillance
• Appendix B: Recommendations for Reporting and Counting Tuberculosis Cases
• Appendix C: National Surveillance for Severe Adverse Events Associated with Treatment for Latent Tuberculosis Infection — Reporting information
• Appendix D: Genotyping Background Information and Glossary

• Surveillance Slide Set, 2017 Cdc-ppt[PPT – 2 MB]
• 2017 Surveillance Slides
• Slide Narratives Cdc-pdf[PDF – 647 KB]